Rare diseases
Investigational molecules
Locations
18 Campus Boulevard Suite 100, 19073-3240, United States
Arrivent Biopharma Inc. focuses on non-small cell lung cancer across locally advanced and metastatic settings, with studies centered on tumors driven by EGFR-related alterations.
The sponsor’s research activity includes treatment settings where targeted therapy is being evaluated against established systemic options in lung cancer care.
Arrivent Biopharma Inc. runs clinical trials in conditions such as Non-small cell lung cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceFranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
